Plaque Psoriasis

Gooderham addresses what the 3-year results of the reSURFACE 2 trial of tildrakizumab for plaque psoriasis mean for prescribers.

The analysis of the UltIMMa 1 & 2 trials of risankizumab demonstrated efficacy and safety in the treatment of moderate-to-severe plaque psoriasis.

This extension study investigated the long-term efficacy and safety of tildrakizumab for patients with plaque psoriasis.

Results from the reSURFACE 1 phase 3 trial shows the biologic is beneficial to patient rates of anxiety, pain, and depression.

Investigators assessed patients’ scores for body surface area, static Physician Global Assessments, and Dermatology QoL Index at 1 month post-index, and at three-month intervals both pre- and post-index.

In this analysis, brodalumab was successful in treating patients who had a psoriasis diagnosis for

New data from AAD show the recently-approved biologic is among the most cost-saving therapies in year 2 of treatment, and beyond.

An internist’s perspective on which sessions to attend, from melanoma to inflammatory diseases to cosmetic procedures.

The FDA has extended the approved use of Bryhali (halobetasol propionate) Lotion .01% for up to 8 weeks in adults with plaque psoriasis.

Novartis reported that 59% of patients at 24 weeks experienced little to no impact of their condition on their quality of life. Additionally, 87% of bio-naïve psoriasis patients remained on secukinumab through 12 months, indicating its tolerability in real-world settings.

The fixed-dose combination therapy from Valeant Pharmaceuticals International is vying to become the first and only approved topical lotion for the condition.

CIMZIA is the first Fc-free biologic of its kind for this patient population.

Taltz (ixekizumab) is the first FDA-approved treatment for moderate to severe plaque psoriasis that includes data on psoriasis in the genital area.

The therapy met all co-primary and ranked secondary endpoints in the 4 trials without displaying any new safety signals, according to AbbVie.

The therapy was approved on the evidence of a pivotal phase 3 clinical development program which tested the efficacy of the inhibitor versus placebo in 926 adult patients.

Patients taking ustekinumab showed a 19% improvement in aortic inflammation compared to placebo.

The label update for secukinumab (Cosentyx, Novartis) now includes the treatment for moderate-to-severe scalp psoriasis.

Nearly half of the study participants achieved complete skin at week 16, while 87% maintained the response at week 52.

The FDA has approved guselkumab for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Patients afflicted with psoriasis have higher odds of developing abdominal aortic aneurysms.

Researchers are closing in on a medical treatment for wart-like skin growths know as seborrheic keratosis.

Seniors who developed the painful rash commonly known as shingles may also be at higher risk of suffering a stroke or heart attack.

College kids who break out or get hives can, in fact, blame some of their skin problems on heightened levels of psychological stress.

Patients with plaque psoriasis often experience clear improvement in their skin conditions after undergoing tonsillectomy.

This 29-year-old man came in for a wellness evaluation but notes having had this rash for 8 years. Occasionally it itches, but otherwise is asymptomatic and he has had no treatment for it to date. He does not take any medications and has no significant past medical history.